Skip to Content

Posts tagged with "Uncategorized"

  • Chemical Biology

    Poke Holes Through Your Membranes. It’s Fun.

    The cell membrane – the fundamental architecture of living things, the foundation of how our very bodies are organized – is a major pain in the behind. I express this ungrateful opinion merely because over the years it has rejected entry to some of my best ideas for drug candidates, and I bear a grudge. Read More
  • Chemical News

    How Many of Those Compounds Are Crap?

    A reader sent along a note about this letter to Nature Medicine earlier in the year. It’s about drug repurposing, and more specifically about the Drug Repurposing Hub at the Broad Institute. This is a collection of nearly 5,000 compounds, curated and annotated with their histories and activities. It was not a straightforward task: . Read More
  • Clinical Trials

    Not How You Speed the Process Up, Exactly

    Now, this truly does not sound like the way to run a clinical trial. Dr. William Halford of the Rational Vaccines company invited 20 patients to St. Kitts for a trial of a putative herpes vaccine. The consent forms explicitly stated that this was done to evade the jurisdiction of the US Food and Drug… Read More
  • Biological News

    Small Proteins: Into the Gap

    We medicinal chemists are used to thinking about small molecule drugs – it’s what we do. And we’re also comfortable with having a category in our worldview that we assign to “biologics” – proteins, mostly, many of them antibodies, which can also be extremely therapeutically effective under the right conditions. B… Read More
  • Chemical News

    The Old School

    I enjoyed this piece on “The Changing Culture of Chemistry”. The author, Bruce Gibb of Tulane, has in mind the changes that are apparent when you read old papers that describe (say) a couple of unidentified people associated with the project ingesting one of the sulfur-containing components of asparagus (asparagusic acid, newly isolated… Read More
  • Business and Markets

    More Movements at the Top of GSK

    GlaxoSmithKline has been having more than its share of ups and downs over the last few years. In 2014, they moved a lot of assets out of oncology, as part of a general rearrangement into higher-volume lower-cost areas. That was a pretty bold move – give management credit for not being timid, at least – Read More
  • Clinical Trials

    When Small Trials Convince

    This is a good piece by Bruce Booth in Forbes, and it points out something that’s changing in the biopharma landscape. Readers will have noticed over the years here the occasional eye-rolling at companies that run underpowered clinical trials and go to the FDA hoping for the best. That’s not a good place to save… Read More
  • Clinical Trials

    Silicon Stays in the Shadows

    I like this review, but I’ve seen it before. Well, not this exact manuscript, but every few years it seems there’s another one with a similar title, something about “Incorporating Silicon Into Drug Structures”. I am guilty of the exact same thing, though: here’s a blog post from 2004 on the topic, and here’s one… Read More
  • Pharmacokinetics

    There’s Toxicity, And There’s Toxicity

    This is a neat article at Bloomberg about the production of botulinum toxin (BTX, aka Botox). This is a drug that has some rather special handling involved: A baby-aspirin-size amount of powdered toxin is enough to make the global supply of Botox for a year. That little bit is derived from a larger primary source… Read More
  • "Me Too" Drugs

    The Drug Project Landscape

    Here’s a new paper in Nature Reviews Drug Discovery that’s going to the trouble of matching specific disease indications with specific mechanisms in drug projects over the last 20 years (both the successful ones and the unsuccessful ones). The authors (from Vertex) used the Cortellis commercial database (with a good deal of filtering an… Read More
...456...